GAMMA Investing
PRLD icon

GAMMA Investing’s Prelude Therapeutics PRLD Stock Holding History

GAMMA Investing’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.94K Buy
+495
New +$2.43K ﹤0.01% 3963

Other funds holding PRLD

Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

GAMMA Investing's PRLD Position: Q3 2026 in Review

GAMMA Investing opened a new position in Prelude Therapeutics (PRLD) in Q3 2026: 495 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #3963 among its holdings.

7 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

  • GAMMA Investing held 495 shares of Prelude Therapeutics worth $1.94K as of Q3 2026.
  • Prelude Therapeutics was a new GAMMA Investing position in Q3 2026.
  • Prelude Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3963 holding.
  • 7 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.